Frank Borriello
Chief Executive Officer Alloplex Biotherapeutics
Frank Borriello is the founder and CEO of Alloplex Biotherapeutics, a private, clinical-stage Boston-based company launched in 2016 based on an original and now patented concept. He obtained his MD, PhD degrees at the Albert Einstein College of Medicine and continued training at the Brigham and Women’s Hospital in Boston with a residency in clinical pathology and a focus in cellular immunology. He has an extensive background in the biotech/pharma industry of over 20 years which span diverse roles in clinical development, biotech financial analysis, external innovation due diligence and business development. Dr. Borriello has lived and worked in the Boston area since 1991.
Seminars
Achieving durable responses in patients remains one of the most important challenges for NK cell therapies. This panel will bring together leaders in academia, biotech, and clinical development to discuss strategies for boosting efficacy, extending persistence, and improving the therapeutic potential of NK-based treatments. Experts will explore how next generation engineering, manufacturing, and clinical insights are shaping the future of innate cell therapies.
- Understanding barriers to efficacy and persistence, examining tumor escape, immunosuppression, and NK cell exhaustion that limit clinical outcomes
- Advancing engineering solutions, exploring cytokine support, gene edits, and checkpoint resistance to strengthen NK cell function in vivo
- Improving translation to the clinic, aligning manufacturing, trial design, and biomarker strategies to achieve more consistent and durable responses
- Developing strategies to enhance NK, persistence, migration, tumor-killing potential and improving safety profiles
- Exploring scalable platforms for making ex vivo cell manufacturing more efficient at reduced cost
